StockpollyBeta
Get App
Popularity #3,722
ANVS · NYSE · Biotechnology

Annovis Bio (ANVS)

Develops oral buntanetap for Alzheimer's and Parkinson's disease.

$1.24
vs last close−0.03 (−1.98%)

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
15108847667101814
Research & development1497635556916,72012,007
12122211111,2922,370
General & administrative12122211111,2922,370
Other expenses0000000000−17,994−14,363
Operating income−15−10−8−8−4−7−6−6−7−10−18−14
0−1273−81100000
Interest income000000000000
Interest expense000110000002
Other non-operating income012−7−48−1−100000
Income before tax−15−22−1−5−13−6−6−6−7−10−18−15
Net income from continuing operations−15−22−1−5−13−6−6−6−7−10−18−15
Net income−15−22−1−5−13−6−6−6−7−10−18−15
EPS, basic−$1.63−$2.33−$0.10−$0.44−$0.97−$0.43−$0.32−$0.32−$0.37−$0.40−$0.63−$0.39
EPS, diluted−$1.63−$2.33−$0.10−$0.44−$0.97−$0.48−$0.32−$0.32−$0.37−$0.40−$0.63−$0.39
Weighted average shares, basic91011111314171920252838
Weighted average shares, diluted91011111314171920252838
EBITDA−15−22−1−4−12−6−6−6−7−10−18−14
Depreciation & amortization000000000000
EBIT−15−22−1−4−12−6−6−6−7−10−18−14